 Andrea Griesinger
Concepts (189)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ependymoma | 15 | 2026 | 176 | 5.140 |
Why?
| | Infratentorial Neoplasms | 8 | 2026 | 71 | 3.690 |
Why?
| | Brain Neoplasms | 9 | 2025 | 1322 | 1.130 |
Why?
| | Nuclear Proteins | 4 | 2025 | 749 | 1.090 |
Why?
| | Trastuzumab | 1 | 2026 | 118 | 0.920 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2026 | 161 | 0.890 |
Why?
| | Immunophenotyping | 2 | 2017 | 322 | 0.850 |
Why?
| | Chromosomes, Human, Pair 1 | 2 | 2019 | 79 | 0.730 |
Why?
| | Chromatin | 2 | 2025 | 561 | 0.700 |
Why?
| | Medulloblastoma | 6 | 2022 | 215 | 0.670 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2026 | 1141 | 0.660 |
Why?
| | Cerebellar Neoplasms | 5 | 2022 | 177 | 0.590 |
Why?
| | NF-kappa B | 2 | 2025 | 662 | 0.580 |
Why?
| | Chemoradiotherapy | 1 | 2019 | 239 | 0.550 |
Why?
| | Supratentorial Neoplasms | 1 | 2018 | 18 | 0.540 |
Why?
| | Transcription Factor RelA | 1 | 2018 | 85 | 0.520 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2026 | 1958 | 0.500 |
Why?
| | Myeloid Cells | 2 | 2015 | 148 | 0.470 |
Why?
| | Cell Proliferation | 7 | 2025 | 2499 | 0.460 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 241 | 0.460 |
Why?
| | Gene Expression Regulation, Neoplastic | 7 | 2022 | 1462 | 0.450 |
Why?
| | Tumor Suppressor Proteins | 1 | 2017 | 321 | 0.450 |
Why?
| | Biomarkers, Tumor | 3 | 2018 | 1322 | 0.410 |
Why?
| | STAT3 Transcription Factor | 1 | 2015 | 207 | 0.390 |
Why?
| | Proto-Oncogene Proteins B-raf | 3 | 2025 | 226 | 0.390 |
Why?
| | Gene Expression Profiling | 8 | 2024 | 1786 | 0.380 |
Why?
| | Tumor Cells, Cultured | 3 | 2025 | 919 | 0.360 |
Why?
| | Tumor Microenvironment | 5 | 2025 | 735 | 0.340 |
Why?
| | Child | 19 | 2026 | 22657 | 0.340 |
Why?
| | Interleukin-6 | 1 | 2015 | 780 | 0.330 |
Why?
| | Cell Line, Tumor | 9 | 2020 | 3550 | 0.330 |
Why?
| | T-Lymphocytes | 3 | 2023 | 1982 | 0.320 |
Why?
| | Glioma | 2 | 2025 | 426 | 0.310 |
Why?
| | Phenotype | 3 | 2024 | 3164 | 0.300 |
Why?
| | Survival Rate | 3 | 2026 | 2092 | 0.300 |
Why?
| | Disease Models, Animal | 1 | 2019 | 4569 | 0.290 |
Why?
| | Signal Transduction | 2 | 2025 | 5233 | 0.260 |
Why?
| | Chromosomes | 2 | 2024 | 108 | 0.250 |
Why?
| | Prognosis | 5 | 2026 | 4293 | 0.250 |
Why?
| | Injections, Spinal | 1 | 2026 | 121 | 0.240 |
Why?
| | Antineoplastic Agents | 4 | 2020 | 2197 | 0.240 |
Why?
| | Mice | 8 | 2025 | 18365 | 0.230 |
Why?
| | Chloroquine | 2 | 2017 | 53 | 0.230 |
Why?
| | Craniopharyngioma | 2 | 2017 | 77 | 0.220 |
Why?
| | Proto-Oncogene Proteins c-myc | 2 | 2019 | 167 | 0.220 |
Why?
| | Ganglioglioma | 1 | 2025 | 34 | 0.220 |
Why?
| | Humans | 31 | 2026 | 144957 | 0.220 |
Why?
| | Neurofibroma, Plexiform | 1 | 2023 | 12 | 0.200 |
Why?
| | Neurofibromatosis 1 | 1 | 2023 | 54 | 0.190 |
Why?
| | Fluorouracil | 1 | 2024 | 235 | 0.190 |
Why?
| | Autophagy | 2 | 2017 | 286 | 0.190 |
Why?
| | Follow-Up Studies | 2 | 2026 | 5417 | 0.190 |
Why?
| | Genes, myc | 2 | 2020 | 51 | 0.190 |
Why?
| | Child, Preschool | 6 | 2026 | 11799 | 0.180 |
Why?
| | Animals | 10 | 2025 | 38109 | 0.180 |
Why?
| | Apoptosis | 4 | 2019 | 2430 | 0.180 |
Why?
| | Indoles | 2 | 2017 | 501 | 0.170 |
Why?
| | Sulfonamides | 2 | 2017 | 581 | 0.170 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2019 | 930 | 0.170 |
Why?
| | Chromosome Aberrations | 2 | 2023 | 163 | 0.170 |
Why?
| | Central Nervous System Neoplasms | 1 | 2023 | 174 | 0.160 |
Why?
| | Cytokines | 3 | 2017 | 2065 | 0.150 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2020 | 82 | 0.150 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2020 | 254 | 0.150 |
Why?
| | Infant | 3 | 2026 | 10039 | 0.150 |
Why?
| | Pyrimidinones | 1 | 2020 | 126 | 0.150 |
Why?
| | Astrocytoma | 2 | 2025 | 129 | 0.150 |
Why?
| | Mice, SCID | 1 | 2019 | 369 | 0.140 |
Why?
| | Immunotherapy, Adoptive | 2 | 2023 | 337 | 0.140 |
Why?
| | SMARCB1 Protein | 1 | 2019 | 34 | 0.140 |
Why?
| | Deoxycytidine | 1 | 2020 | 221 | 0.140 |
Why?
| | Osteomyelitis | 1 | 2020 | 143 | 0.140 |
Why?
| | Pyrazoles | 2 | 2020 | 510 | 0.140 |
Why?
| | Transcriptome | 5 | 2025 | 1046 | 0.140 |
Why?
| | Cohort Studies | 4 | 2018 | 5965 | 0.140 |
Why?
| | Cell Cycle Proteins | 2 | 2020 | 629 | 0.140 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 610 | 0.130 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2018 | 191 | 0.130 |
Why?
| | Cyst Fluid | 1 | 2017 | 20 | 0.130 |
Why?
| | Teratoma | 1 | 2019 | 120 | 0.130 |
Why?
| | Rhabdoid Tumor | 1 | 2019 | 103 | 0.130 |
Why?
| | Single-Cell Analysis | 1 | 2020 | 359 | 0.130 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2020 | 433 | 0.120 |
Why?
| | Checkpoint Kinase 1 | 1 | 2016 | 27 | 0.120 |
Why?
| | Epigenesis, Genetic | 2 | 2021 | 685 | 0.120 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2019 | 339 | 0.120 |
Why?
| | Microarray Analysis | 4 | 2017 | 117 | 0.120 |
Why?
| | Histones | 1 | 2021 | 670 | 0.120 |
Why?
| | Pituitary Neoplasms | 1 | 2017 | 190 | 0.110 |
Why?
| | EGF Family of Proteins | 1 | 2015 | 17 | 0.110 |
Why?
| | Transcriptional Activation | 1 | 2017 | 383 | 0.110 |
Why?
| | Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2015 | 16 | 0.110 |
Why?
| | Receptor, EphA2 | 1 | 2015 | 17 | 0.110 |
Why?
| | Receptor, ErbB-3 | 1 | 2015 | 48 | 0.110 |
Why?
| | Molecular Targeted Therapy | 1 | 2018 | 434 | 0.110 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2015 | 87 | 0.110 |
Why?
| | src-Family Kinases | 1 | 2015 | 93 | 0.110 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2017 | 883 | 0.100 |
Why?
| | Receptors, IgG | 1 | 2013 | 76 | 0.100 |
Why?
| | RNA, Messenger | 3 | 2017 | 2832 | 0.100 |
Why?
| | Promoter Regions, Genetic | 1 | 2017 | 1258 | 0.090 |
Why?
| | HLA-DR Antigens | 1 | 2013 | 220 | 0.090 |
Why?
| | Male | 9 | 2026 | 72406 | 0.090 |
Why?
| | Monocytes | 1 | 2015 | 538 | 0.090 |
Why?
| | Inflammation Mediators | 1 | 2015 | 509 | 0.090 |
Why?
| | ErbB Receptors | 1 | 2015 | 629 | 0.090 |
Why?
| | Central Nervous System | 1 | 2014 | 281 | 0.090 |
Why?
| | Female | 9 | 2026 | 78376 | 0.090 |
Why?
| | Adolescent | 5 | 2025 | 22453 | 0.090 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 381 | 0.090 |
Why?
| | Treatment Outcome | 2 | 2024 | 11695 | 0.080 |
Why?
| | Phosphorylation | 1 | 2015 | 1733 | 0.080 |
Why?
| | Neoplastic Stem Cells | 1 | 2014 | 412 | 0.080 |
Why?
| | Glioblastoma | 1 | 2013 | 353 | 0.080 |
Why?
| | Transcription Factors | 2 | 2017 | 1742 | 0.080 |
Why?
| | Epilepsy | 1 | 2013 | 387 | 0.070 |
Why?
| | Azepines | 2 | 2019 | 107 | 0.060 |
Why?
| | Triazoles | 2 | 2019 | 184 | 0.060 |
Why?
| | Mice, Nude | 2 | 2019 | 688 | 0.050 |
Why?
| | Drug Synergism | 2 | 2017 | 357 | 0.050 |
Why?
| | X-ray Repair Cross Complementing Protein 1 | 1 | 2023 | 13 | 0.050 |
Why?
| | Intelligence Tests | 1 | 2023 | 56 | 0.050 |
Why?
| | Mice, Transgenic | 2 | 2020 | 2185 | 0.050 |
Why?
| | RNA, Small Nuclear | 1 | 2023 | 38 | 0.050 |
Why?
| | Cell Survival | 2 | 2017 | 1098 | 0.050 |
Why?
| | Young Adult | 2 | 2018 | 14126 | 0.050 |
Why?
| | Cranial Irradiation | 1 | 2023 | 85 | 0.050 |
Why?
| | Quality of Life | 1 | 2015 | 3192 | 0.050 |
Why?
| | Ligands | 1 | 2023 | 674 | 0.040 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2023 | 220 | 0.040 |
Why?
| | Epigenomics | 1 | 2021 | 114 | 0.040 |
Why?
| | Brain | 1 | 2013 | 2941 | 0.040 |
Why?
| | Symptom Flare Up | 1 | 2020 | 37 | 0.040 |
Why?
| | Adult | 3 | 2023 | 40506 | 0.040 |
Why?
| | Hedgehog Proteins | 1 | 2022 | 197 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2021 | 187 | 0.040 |
Why?
| | Induction Chemotherapy | 1 | 2020 | 87 | 0.040 |
Why?
| | Drug Substitution | 1 | 2020 | 63 | 0.040 |
Why?
| | Homozygote | 1 | 2020 | 199 | 0.040 |
Why?
| | Survival Analysis | 1 | 2023 | 1385 | 0.040 |
Why?
| | Survivors | 1 | 2023 | 520 | 0.040 |
Why?
| | Mutation | 2 | 2025 | 4099 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2023 | 668 | 0.040 |
Why?
| | Cell Self Renewal | 1 | 2019 | 53 | 0.040 |
Why?
| | Neuropsychological Tests | 1 | 2023 | 1137 | 0.040 |
Why?
| | Interleukin-1beta | 1 | 2020 | 395 | 0.040 |
Why?
| | Injections, Intraventricular | 1 | 2018 | 58 | 0.030 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2019 | 142 | 0.030 |
Why?
| | Drug Approval | 1 | 2018 | 91 | 0.030 |
Why?
| | Antirheumatic Agents | 1 | 2020 | 304 | 0.030 |
Why?
| | Receptors, HIV | 1 | 2017 | 23 | 0.030 |
Why?
| | Mucin-1 | 1 | 2017 | 22 | 0.030 |
Why?
| | Cytogenetic Analysis | 1 | 2017 | 33 | 0.030 |
Why?
| | Macaca mulatta | 1 | 2018 | 191 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2018 | 170 | 0.030 |
Why?
| | Receptors, Interleukin-6 | 1 | 2017 | 47 | 0.030 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2017 | 55 | 0.030 |
Why?
| | Ki-67 Antigen | 1 | 2017 | 117 | 0.030 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2017 | 125 | 0.030 |
Why?
| | RNA | 1 | 2023 | 940 | 0.030 |
Why?
| | Benzodiazepinones | 1 | 2016 | 18 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 2020 | 826 | 0.030 |
Why?
| | Cellular Senescence | 1 | 2019 | 226 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2017 | 321 | 0.030 |
Why?
| | Urea | 1 | 2016 | 84 | 0.030 |
Why?
| | Thiophenes | 1 | 2016 | 128 | 0.030 |
Why?
| | Disease Progression | 1 | 2023 | 2852 | 0.030 |
Why?
| | Amphiregulin | 1 | 2015 | 27 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 769 | 0.030 |
Why?
| | Cisplatin | 1 | 2016 | 334 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 988 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 966 | 0.030 |
Why?
| | Computer Simulation | 1 | 2018 | 1026 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2014 | 341 | 0.020 |
Why?
| | Imaging, Three-Dimensional | 1 | 2017 | 583 | 0.020 |
Why?
| | Up-Regulation | 1 | 2015 | 852 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2014 | 758 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 983 | 0.020 |
Why?
| | Blotting, Western | 1 | 2014 | 1187 | 0.020 |
Why?
| | Cell Cycle | 1 | 2014 | 597 | 0.020 |
Why?
| | Gene Expression | 1 | 2015 | 1490 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 2017 | 1500 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1718 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2147 | 0.010 |
Why?
| | Risk Factors | 1 | 2018 | 10792 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2015 | 6434 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2013 | 8279 | 0.010 |
Why?
| | Aged | 1 | 2013 | 25947 | 0.010 |
Why?
| | Middle Aged | 1 | 2013 | 35928 | 0.010 |
Why?
|
|
Griesinger's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|